What is the latest ONESOURCE stock price?
The latest stored price for ONESOURCE is Rs 1,461.30 as of 2026-10-09.
gimli
ONESOURCE stock AI analysis
ONESOURCE Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
ONESOURCE SPECL PHARMA L is a small-cap stock in Healthcare. This Gimli page shows the latest available ONESOURCE price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹1,461.30
1W return
-3.10%
1M return
-4.50%
3M return
-10.11%
6M return
+6.22%
1Y return
-22.67%
Market cap
₹16,753.19 cr
PE
-344.57
PB
2.87
ROE
-0.83%
ROCE
+0.82%
RSI
35.90
Turnover
₹28.43 cr
Why it can matter in screens
- Momentum: ONESOURCE is below 50DMA, below 200DMA; RSI is 35.90.
- Returns: 1D -1.14%, 1W -3.10%, 1M -4.50%, 3M -10.11%, 1Y -22.67%.
- Trend levels: 52W high ₹1,895.00, 52W low ₹1,433.60, off high -22.89%.
- Liquidity: latest turnover is ₹28.43 cr; volume vs 20D is +0.67%.
- Valuation/profitability: PE -344.57, PB 2.87, ROE -0.83%, ROCE +0.82%.
- Growth: 3Y sales CAGR +232.30%, 3Y profit CAGR n/a.
Quick Answers
Is ONESOURCE above its 50DMA and 200DMA?
ONESOURCE is below 50DMA, below 200DMA. The latest 50DMA is 1,554.51 and the latest 200DMA is 1,575.52.
What are ONESOURCE PE, ROE and ROCE?
ONESOURCE has PE -344.57, ROE -0.83%, and ROCE +0.82% in Gimli's latest available snapshot.
How has ONESOURCE performed recently?
ONESOURCE has returned -4.50% over 1 month, -10.11% over 3 months, and -22.67% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 449.02 cr | 122.85 cr | 25.00 cr | 2.18 |
| 2026-03-31 | 428.22 cr | 94.05 cr | 4.60 cr | 0.40 |
| 2025-12-31 | 290.34 cr | 14.86 cr | -88.70 cr | -7.74 |
| 2025-09-30 | 375.76 cr | 109.53 cr | 10.48 cr | 0.92 |
| 2025-06-30 | 327.27 cr | 90.88 cr | -0.19 cr | -0.02 |
| 2025-03-31 | 425.95 cr | 185.41 cr | 98.50 cr | 8.61 |
| 2024-06-30 | 292.29 cr | 63.78 cr | -5.55 cr | -0.48 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 1,421.59 cr | 309.32 cr | -73.80 cr | -6.44 |
| 2025-03-31 | 1,444.85 cr | 373.14 cr | -17.97 cr | -1.63 |
| 2024-03-31 | 171.92 cr | -184.92 cr | -391.17 cr | -34.18 |
| 2023-03-31 | 38.71 cr | -261.44 cr | -799.83 cr | -69.89 |
| 2022-03-31 | 137.99 cr | -91.37 cr | -229.74 cr | 0.00 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 8,210.01 cr | 35.68 cr | 1,503.94 cr | 5,831.29 cr |
| 2025-03-31 | 7,550.24 cr | 156.48 cr | 942.44 cr | 5,880.58 cr |
| 2024-03-31 | 1,308.61 cr | 6.47 cr | 571.17 cr | 395.71 cr |
| 2023-03-31 | 2,008.81 cr | 4.97 cr | 864.22 cr | 785.45 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 8.52 cr | -560.55 cr | n/a |
| 2025-03-31 | -67.85 cr | -196.00 cr | n/a |
| 2024-03-31 | -107.21 cr | -170.98 cr | n/a |
| 2023-03-31 | -162.76 cr | -206.76 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +30.48% | +19.19% | +23.38% | +12.98% | +26.94% | +37.23% |
| 2026-03-31 | +30.48% | +17.50% | +20.61% | +10.13% | +31.41% | +38.38% |
| 2025-12-31 | +29.93% | +19.24% | +18.81% | +9.02% | +32.02% | +18.52% |
| 2025-09-30 | +29.77% | +19.39% | +18.49% | +8.99% | +32.35% | +26.04% |
| 2025-06-30 | +29.79% | +18.69% | +18.10% | +9.06% | +33.42% | +25.01% |
| 2025-03-31 | +34.25% | +18.54% | +18.04% | +8.32% | +29.17% | +20.06% |
| 2024-12-31 | +37.77% | +17.44% | +12.56% | +4.62% | +32.23% | +9.58% |
| 2024-12-01 | +37.77% | +17.44% | +12.56% | +4.62% | +32.23% | +9.58% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 422,282.96 cr | 34.857273 | +15.50% | +6.12% |
| DIVISLAB | DIVI S LABORATORIES LTD | 247,947.67 cr | 85.088426 | +18.37% | +52.32% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 157,610.64 cr | 72.265309 | +17.33% | +31.16% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 115,423.17 cr | 58.937484 | +21.03% | +4.32% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,446.65 cr | 25.058308 | +16.04% | +12.37% |
| LAURUSLABS | LAURUS LABS LIMITED | 109,947.20 cr | 100.670416 | +21.77% | +135.42% |
| CIPLA | CIPLA LTD | 105,094.85 cr | 31.162389 | +10.25% | -14.02% |
| DRREDDY | DR. REDDY S LABORATORIES | 99,661.60 cr | 30.096514 | +9.23% | -3.94% |
Try these prompts
- Analyze ONESOURCE SPECL PHARMA L with valuation, momentum and industry peers
- Compare ONESOURCE with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare ONESOURCE with other Healthcare stocks
Data snapshot: 2026-10-09. Not investment advice.